Paul M. Magtibay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Paul M. Magtibay has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Javier F. Magrina
Department of Medical and Surgical Gynecology, Mayo Clinic, 5779 E. Mayo Blvd., 3(rd) Floor, Phoenix, 85054, Arizona, USA
3 shared publications - Augusto Pereira
Department of Gynecologic Oncology, Hospital Universitario Puerta de Hierro de Majadahonda, 28222 Madrid, Spain
2 shared publications Karl C. Podratz
2 shared publicationsKristina Butler
Department of Obstetrics and Gynecology
2 shared publications- Ritchie Delara
Department of Medical and Surgical Gynecology, Mayo Clinic, Phoenix, AZ, USA
2 shared publications - Tirso Pérez-Medina
Hospital Universitario Puerta de Hierro, 28222 Majadahonda, Madrid, Spain
2 shared publications
Latest Publications
- Open Access
Does MIS Play a Role in the Treatment of Advanced Ovarian Cancer?
Neoadjuvant chemotherapy allows a minimally invasive approach for interval debulking in patients with ovarian cancer considered unresectable to no residual disease by laparotomy at diagnosis. The aim of the study was to evaluate the type of surgical approach at interval debulking (ID) after three courses of carboplatin and taxol in patients with unresectable ovarian cancer at diagnosis compared with the type of surgical approach at primary debulking (PD). A secondary objective was to compare the perioperative outcomes of MIS vs. laparotomy at ID. A retrospective review of the type of surgical approach at ID following three courses of carboplatin and taxol was compared with the surgical approach at PD, and a review of the perioperative outcomes of MIS vs. open at ID was performed during the period from 21 January 2012, through 21 February 2013, for stage IIIC > 2 cm or IV epithelial ovarian cancer (EOC) unresectable at diagnosis and the surgical approach at PD. During the study period, 127 patients with stage IIIC or IV EOC met the inclusion criteria. Minimally invasive surgery (MIS), laparoscopic or robotic, was used in 21.6% of patients at ID and in 23.3% of patients at PD. At ID, MIS patients had a shorter hospital stay as compared to laparotomy (2 vs. 8 days; p < 0.001). At 5 year follow-up, 31.5% of EOC patients were alive (ID MIS: 47.5% vs. ID open: 30%; PD MIS: 41% vs. PD open: 28%), while 24.4% had no evidence of disease (ID MIS: 39% vs. ID open: 19.5%; PD MIS: 32% vs. PD open: 22%). Among living patients, 22% had evidence of disease. Neoadjuvant chemotherapy is a form of chemo-debulking and allows a minimally invasive approach at interval debulking in about one-fifth of the patients, with initial disease deemed unresectable to no residual tumor at initial diagnosis.
Open AccessDoes MIS Play a Role in the Treatment of Advanced Ovarian Cancer?
Neoadjuvant chemotherapy allows a minimally invasive approach for interval debulking in patients with ovarian cancer considered unresectable to no residual disease by laparotomy at diagnosis. The aim of the study was to evaluate the type of surgical approach at interval debulking (ID) after three courses of carboplatin and taxol in patients with unresectable ovarian cancer at diagnosis compared with the type of surgical approach at primary debulking (PD). A secondary objective was to compare the perioperative outcomes of MIS vs. laparotomy at ID. A retrospective review of the type of surgical approach at ID following three courses of carboplatin and taxol was compared with the surgical approach at PD, and a review of the perioperative outcomes of MIS vs. open at ID was performed during the period from 21 January 2012, through 21 February 2013, for stage IIIC > 2 cm or IV epithelial ovarian cancer (EOC) unresectable at diagnosis and the surgical approach at PD. During the study period, 127 patients with stage IIIC or IV EOC met the inclusion criteria. Minimally invasive surgery (MIS), laparoscopic or robotic, was used in 21.6% of patients at ID and in 23.3% of patients at PD. At ID, MIS patients had a shorter hospital stay as compared to laparotomy (2 vs. 8 days; p < 0.001). At 5 year follow-up, 31.5% of EOC patients were alive (ID MIS: 47.5% vs. ID open: 30%; PD MIS: 41% vs. PD open: 28%), while 24.4% had no evidence of disease (ID MIS: 39% vs. ID open: 19.5%; PD MIS: 32% vs. PD open: 22%). Among living patients, 22% had evidence of disease. Neoadjuvant chemotherapy is a form of chemo-debulking and allows a minimally invasive approach at interval debulking in about one-fifth of the patients, with initial disease deemed unresectable to no residual tumor at initial diagnosis.
- Open Access
- 16 February 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (2) , 289
Granulomatosis with Polyangiitis-Mimicking Advanced Gynecological Cancer: A Case Report and Systematic Review of the Literature
(1) Background: Granulomatosis with polyangiitis (GPA) is a necrotizing vasculitis that mimics gynecologic cancer. In GPA patients, the genitourinary system is affected in <1%. The objective of the study was to provide a systematic review of the literature of GPA patients with gynecological involvement. (2) Methods: PubMed and Embase were searched from inception to July 2021 for GPA patients with gynecological involvement Medical Subject Headings (MeSH) and free-text terms. Exclusion criteria were other language, review articles, pregnancy, fertility, or male patients. Data were extracted on clinical evolution, symptoms, examinations findings, diagnosis delay, treatment, outcome, patient status, and follow-up. (3) Results: Seventeen studies included data from patients with GPA and primary or relapsed gynecological involvement. 68% of the authors of this review thought the patient had cancer. The main gynecological symptom is bleeding, but exclusive gynecologic symptomatology is rare (ENT: 63%, lungs: 44%, kidneys-urinary tract: 53%). GPA could affect all areas of the genital tract, but the most frequent location is the uterine cervix. Medical treatment for GPA is effective. (4) Conclusions: GPA of the female genital tract must be considered when biopsies of an ulcerated malignant-appearing cervical or vaginal mass are negative for malignancy even when they are unspecific. Rheumatology consultation is indicated.
- 16 February 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (2) , 289
Open AccessGranulomatosis with Polyangiitis-Mimicking Advanced Gynecological Cancer: A Case Report and Systematic Review of the Literature
(1) Background: Granulomatosis with polyangiitis (GPA) is a necrotizing vasculitis that mimics gynecologic cancer. In GPA patients, the genitourinary system is affected in <1%. The objective of the study was to provide a systematic review of the literature of GPA patients with gynecological involvement. (2) Methods: PubMed and Embase were searched from inception to July 2021 for GPA patients with gynecological involvement Medical Subject Headings (MeSH) and free-text terms. Exclusion criteria were other language, review articles, pregnancy, fertility, or male patients. Data were extracted on clinical evolution, symptoms, examinations findings, diagnosis delay, treatment, outcome, patient status, and follow-up. (3) Results: Seventeen studies included data from patients with GPA and primary or relapsed gynecological involvement. 68% of the authors of this review thought the patient had cancer. The main gynecological symptom is bleeding, but exclusive gynecologic symptomatology is rare (ENT: 63%, lungs: 44%, kidneys-urinary tract: 53%). GPA could affect all areas of the genital tract, but the most frequent location is the uterine cervix. Medical treatment for GPA is effective. (4) Conclusions: GPA of the female genital tract must be considered when biopsies of an ulcerated malignant-appearing cervical or vaginal mass are negative for malignancy even when they are unspecific. Rheumatology consultation is indicated.
- Open Access
- 19 November 2021
- Published by Elsevier in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 5 (6) , 1081-1088
Radical Extirpation With Intraoperative Radiotherapy for Locally Recurrent Gynecologic Cancer: An Institutional Review
- 19 November 2021
- Published by Elsevier in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 5 (6) , 1081-1088
Open AccessRadical Extirpation With Intraoperative Radiotherapy for Locally Recurrent Gynecologic Cancer: An Institutional Review
- 1 September 2020
- Published by Elsevier in Gynecologic Oncology
- Vol. 158 (3) , 555-561
Tumor-free margins and local recurrence in squamous cell carcinoma of the vulva
- 1 September 2020
- Published by Elsevier in Gynecologic Oncology
- Vol. 158 (3) , 555-561
Tumor-free margins and local recurrence in squamous cell carcinoma of the vulva
- Open Access
- 22 April 2018
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 7 (4) , 87
Colorectal-Vaginal Fistulas: Imaging and Novel Interventional Treatment Modalities
Colovaginal and/or rectovaginal fistulas cause significant and distressing symptoms, including vaginitis, passage of flatus/feces through the vagina, and painful skin excoriation. These fistulas can be a challenging condition to treat. Although most fistulas can be treated with surgical repair, for those patients who are not operative candidates, limited options remain. As minimally-invasive interventional techniques have evolved, the possibility of fistula occlusion has enriched the therapeutic armamentarium for the treatment of these complex patients. In order to offer optimal treatment options to these patients, it is important to understand the imaging and anatomical features which may appropriately guide the surgeon and/or interventional radiologist during pre-procedural planning.
- 22 April 2018
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 7 (4) , 87
Open AccessColorectal-Vaginal Fistulas: Imaging and Novel Interventional Treatment Modalities
Colovaginal and/or rectovaginal fistulas cause significant and distressing symptoms, including vaginitis, passage of flatus/feces through the vagina, and painful skin excoriation. These fistulas can be a challenging condition to treat. Although most fistulas can be treated with surgical repair, for those patients who are not operative candidates, limited options remain. As minimally-invasive interventional techniques have evolved, the possibility of fistula occlusion has enriched the therapeutic armamentarium for the treatment of these complex patients. In order to offer optimal treatment options to these patients, it is important to understand the imaging and anatomical features which may appropriately guide the surgeon and/or interventional radiologist during pre-procedural planning.
- 11 January 2011
- Published by Cambridge University Press (CUP)
- p. 435-498
GYNECOLOGIC MALIGNANCY
Laparoscopy has been used for second-look assessments in ovarian cancer since first described in 1973 by Bagley et al. However, it was new developments in equipment and instrumentation, such as videolaparoscopy, high pressure insufflators, and energy sources, in the late 1980s to early 1990s — combined with the work of some of the pioneers of laparoscopic surgery — that made the use of operative laparoscopy in gynecologic oncology feasible. Dargent and Salvat, Querleu et al., and Nezhat et al. first established the safety and practicability of laparoscopic retroperitoneal and intraperitoneal lymphadenectomy and radical hysterectomy. An increasing number of surgeons have since used advanced operative techniques for evaluation and surgical management of gynecologic cancers.Laparoscopy has the benefit of image magnification to aid in identification of metastatic or recurrent disease, especially in areas such as the upper abdomen, liver and diaphragm surfaces, posterior cul-de-sac, bowel, and mesenteric surfaces. In addition, challenging retroperitoneal spaces of the pelvis, such as the paravesical, pararectal, vesicovaginal, and especially the rectovaginal space, can be accessed laparoscopically. Additional benefits of laparoscopy in gynecologic oncology surgery include limited bleeding from small vessels due to the pressure established by pneumoperitoneum, elimination of large abdominal incisions, shortened hospital stay, and rapid recovery.
- 11 January 2011
- Published by Cambridge University Press (CUP)
- p. 435-498
GYNECOLOGIC MALIGNANCY
Laparoscopy has been used for second-look assessments in ovarian cancer since first described in 1973 by Bagley et al. However, it was new developments in equipment and instrumentation, such as videolaparoscopy, high pressure insufflators, and energy sources, in the late 1980s to early 1990s — combined with the work of some of the pioneers of laparoscopic surgery — that made the use of operative laparoscopy in gynecologic oncology feasible. Dargent and Salvat, Querleu et al., and Nezhat et al. first established the safety and practicability of laparoscopic retroperitoneal and intraperitoneal lymphadenectomy and radical hysterectomy. An increasing number of surgeons have since used advanced operative techniques for evaluation and surgical management of gynecologic cancers.Laparoscopy has the benefit of image magnification to aid in identification of metastatic or recurrent disease, especially in areas such as the upper abdomen, liver and diaphragm surfaces, posterior cul-de-sac, bowel, and mesenteric surfaces. In addition, challenging retroperitoneal spaces of the pelvis, such as the paravesical, pararectal, vesicovaginal, and especially the rectovaginal space, can be accessed laparoscopically. Additional benefits of laparoscopy in gynecologic oncology surgery include limited bleeding from small vessels due to the pressure established by pneumoperitoneum, elimination of large abdominal incisions, shortened hospital stay, and rapid recovery.
- 27 January 2009
- Published by Springer Nature in Surgical Endoscopy
- Vol. 23 (10) , 2390-2394
Robotic-assisted sacrocolpopexy: technique and learning curve
Laparoscopic sacrocolpopexy (LSCP) offers a minimally invasive approach for treating vaginal vault prolapse. The Da Vinci robotic surgical system may decrease the difficulty of the procedure. The objective of this study was to describe the surgical technique of robotic-assisted sacrocolpopexy (RASCP) and evaluate its feasibility, safety, learning curve, and perioperative complications. Eighty patients underwent RASCP between November 2004 and June 2007. Robotic dissection of the planes between the bladder and vagina anteriorly and between the vagina and rectum posteriorly was performed. A peritoneal incision was made to expose the sacral promontory and extended down to the vaginal apex. A Y-shaped mesh was sutured to the anterior and posterior surfaces of the vagina. The tail end of the mesh was sutured to the sacral promontory. Intracorporeal knot tying was used in all sutures. The peritoneal incision was closed to cover the mesh using a running suture. Mean operative time was 197.9 [standard deviation (SD) 66.8] min. After completion of the first ten cases, mean operative time decreased by 25.4% [64.3 min, 95% confidence interval (CI) 16.1–112.4 min, p < 0.01]. Two (2.5%) patients had injury to the bladder, one (1.2%) patient had a small bowel injury, and one (1.2%) patient had a ureteric injury. Postoperatively, five (6%) patients developed vaginal mesh erosion, one (1.2%) patient developed a pelvic abscess, and one (1.2%) patient had postoperative ileus. Four (5%) cases were converted to laparotomy. Mean follow-up period was 4.8 months (range 1–24 months). RASCP is a feasible procedure with acceptable complication rates and short learning curve.
- 27 January 2009
- Published by Springer Nature in Surgical Endoscopy
- Vol. 23 (10) , 2390-2394
Robotic-assisted sacrocolpopexy: technique and learning curve
Laparoscopic sacrocolpopexy (LSCP) offers a minimally invasive approach for treating vaginal vault prolapse. The Da Vinci robotic surgical system may decrease the difficulty of the procedure. The objective of this study was to describe the surgical technique of robotic-assisted sacrocolpopexy (RASCP) and evaluate its feasibility, safety, learning curve, and perioperative complications. Eighty patients underwent RASCP between November 2004 and June 2007. Robotic dissection of the planes between the bladder and vagina anteriorly and between the vagina and rectum posteriorly was performed. A peritoneal incision was made to expose the sacral promontory and extended down to the vaginal apex. A Y-shaped mesh was sutured to the anterior and posterior surfaces of the vagina. The tail end of the mesh was sutured to the sacral promontory. Intracorporeal knot tying was used in all sutures. The peritoneal incision was closed to cover the mesh using a running suture. Mean operative time was 197.9 [standard deviation (SD) 66.8] min. After completion of the first ten cases, mean operative time decreased by 25.4% [64.3 min, 95% confidence interval (CI) 16.1–112.4 min, p < 0.01]. Two (2.5%) patients had injury to the bladder, one (1.2%) patient had a small bowel injury, and one (1.2%) patient had a ureteric injury. Postoperatively, five (6%) patients developed vaginal mesh erosion, one (1.2%) patient developed a pelvic abscess, and one (1.2%) patient had postoperative ileus. Four (5%) cases were converted to laparotomy. Mean follow-up period was 4.8 months (range 1–24 months). RASCP is a feasible procedure with acceptable complication rates and short learning curve.
- 12 March 2008
- Published by Wiley in Anatomical Sciences Education
- Vol. 1 (2) , 92-93
Traditional cadaveric anatomy…Gross! Endoscopic anatomy is where it is at
- 12 March 2008
- Published by Wiley in Anatomical Sciences Education
- Vol. 1 (2) , 92-93
Traditional cadaveric anatomy…Gross! Endoscopic anatomy is where it is at
- 1 September 2006
- Published by Wolters Kluwer Health in Clinical Obstetrics and Gynecology
- Vol. 49 (3) , 526-534
Ovarian Remnant Syndrome
Ovarian remnant syndrome (ORS) refers to a condition occurring in women who have had a bilateral salpingo-oophorectomy (BSO), with or without a hysterectomy, that leaves behind ovarian tissue. This residual ovarian tissue then results in pelvic pain or a pelvic mass. Risk factors associated with incomplete removal of an ovary and subsequent development of ORS include a history of endometriosis, pelvic inflammatory disease, multiple previous surgeries, and pelvic adhesive disease. Patients most frequently present with chronic pelvic pain, pelvic pain associated with a pelvic mass, or an asymptomatic pelvic mass. Definitive criteria for diagnosis of ORS include a history of BSO with histologic documentation of ovarian tissue obtained during subsequent surgical excision. The recommended treatment for ORS is surgical excision by laparotomy or, more recently, laparoscopy. We present the presentation and management of patients with ORS and a review of the published literature.
- 1 September 2006
- Published by Wolters Kluwer Health in Clinical Obstetrics and Gynecology
- Vol. 49 (3) , 526-534
Ovarian Remnant Syndrome
Ovarian remnant syndrome (ORS) refers to a condition occurring in women who have had a bilateral salpingo-oophorectomy (BSO), with or without a hysterectomy, that leaves behind ovarian tissue. This residual ovarian tissue then results in pelvic pain or a pelvic mass. Risk factors associated with incomplete removal of an ovary and subsequent development of ORS include a history of endometriosis, pelvic inflammatory disease, multiple previous surgeries, and pelvic adhesive disease. Patients most frequently present with chronic pelvic pain, pelvic pain associated with a pelvic mass, or an asymptomatic pelvic mass. Definitive criteria for diagnosis of ORS include a history of BSO with histologic documentation of ovarian tissue obtained during subsequent surgical excision. The recommended treatment for ORS is surgical excision by laparotomy or, more recently, laparoscopy. We present the presentation and management of patients with ORS and a review of the published literature.
- 1 August 2006
- Published by Elsevier in Gynecologic Oncology
- Vol. 102 (2) , 369-374
Splenectomy as part of cytoreductive surgery in ovarian cancer
- 1 August 2006
- Published by Elsevier in Gynecologic Oncology
- Vol. 102 (2) , 369-374
Splenectomy as part of cytoreductive surgery in ovarian cancer